Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (11-20 of 299) with videos related to

Pageof 30
Sort By:
The New England Journal of Medicine|September 8, 2006
Molecular profiling of a tumor of unknown originGustavo Ismael, Evandro de Azambuja, Ahmad Awada
Current Opinion in Oncology|October 10, 2018
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancerMatteo Lambertini, Giulia Viglietti, Evandro de Azambuja
Expert Opinion on Drug Metabolism & Toxicology|November 2, 2017
Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patientsGil Awada, Evandro de Azambuja, Ahmad Awada
NPJ Breast Cancer|March 17, 2023
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Expert Review of Anticancer Therapy|October 22, 2013
Clinical practice-changing trials: the HERA study paradigmDimitrios Zardavas, Felipe Ades, Evandro de Azambuja
ESMO Open|November 16, 2016
Threat posed by unproven drugs in medical oncologyNoam Pondé, Felipe Ades, Evandro de Azambuja
Oncology and Therapy|November 21, 2023
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?Elisa Agostinetto, Luca Arecco, Evandro de Azambuja
ESMO Open|April 12, 2018
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?Matteo Lambertini, Giulia Viglietti, Evandro de Azambuja
ESMO Open|February 2, 2018
Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?Francesca Poggio, Matteo Lambertini, Evandro de Azambuja
The Lancet. Oncology|May 3, 2019
Denosumab in early-stage breast cancerMariana Brandão, Márcio Debiasi, Evandro de Azambuja
Pageof 30

Showing results (11-20 of 299) with videos related to

Sort By:
Pageof 30
The New England Journal of Medicine|September 8, 2006
Molecular profiling of a tumor of unknown originGustavo Ismael, Evandro de Azambuja, Ahmad Awada
Current Opinion in Oncology|October 10, 2018
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancerMatteo Lambertini, Giulia Viglietti, Evandro de Azambuja
Expert Opinion on Drug Metabolism & Toxicology|November 2, 2017
Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patientsGil Awada, Evandro de Azambuja, Ahmad Awada
NPJ Breast Cancer|March 17, 2023
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Expert Review of Anticancer Therapy|October 22, 2013
Clinical practice-changing trials: the HERA study paradigmDimitrios Zardavas, Felipe Ades, Evandro de Azambuja
ESMO Open|November 16, 2016
Threat posed by unproven drugs in medical oncologyNoam Pondé, Felipe Ades, Evandro de Azambuja
Oncology and Therapy|November 21, 2023
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?Elisa Agostinetto, Luca Arecco, Evandro de Azambuja
ESMO Open|April 12, 2018
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?Matteo Lambertini, Giulia Viglietti, Evandro de Azambuja
ESMO Open|February 2, 2018
Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?Francesca Poggio, Matteo Lambertini, Evandro de Azambuja
The Lancet. Oncology|May 3, 2019
Denosumab in early-stage breast cancerMariana Brandão, Márcio Debiasi, Evandro de Azambuja
Pageof 30